The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
Regeneron is facing two FDA decisions for its T-cell engagers.
The Avanzar study could read out shortly.
The company reckons its immunotherapy could improve on Keytruda.
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
Satri-cel is filed for gastric cancer approval in China.
“We need all the capital we can get our hands on," the company states.
